Abstract
ONTARGET has established the efficacy of the angiotensin receptor blocker (ARB) telmisartan to slow disease progression and delay or prevent morbid events in patients with atherosclerosis. Although the study failed to confirm additive efficacy of telmisartan and the angiotensin-converting-enzyme (ACE) inhibitor ramipril, caution should be exercised in assuming that the mean response in a clinical trial applies to individual patients who might benefit from combination therapy. Physicians should also recognize that the design of the study, in which full doses of the ACE inhibitor and the ARB were administered, might not replicate clinical practice, where one drug is usually added to the other.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yusuf S et al. for the ONTARGET Investigators (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547–1559
Gottlieb SS et al. (1993) Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 88: 1602–1609
Cohn JN and Tognoni G for the Valsartan Heart Failure Trial Investigators (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667–1675
McMurray JJ et al. for the CHARM Investigators and Committees (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362: 767–771
Mogensen CE et al. (2000) Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lininopril microalbuminuria (CALM) study. BMJ 321: 1440–1444
Pfeffer MA et al. for the Valsartan in Acute Myocardial Infarction Trial Investigators (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893–1906
Krum H et al. (2004) Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 6: 937–945
Author information
Authors and Affiliations
Ethics declarations
Competing interests
JN Cohn has acted as a Consultant for Novartis.
Rights and permissions
About this article
Cite this article
Cohn, J. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?. Nat Rev Cardiol 5, 526–527 (2008). https://doi.org/10.1038/ncpcardio1303
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio1303